Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2006-05-30
2006-05-30
Brumback, Brenda (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085400, C424S085100
Reexamination Certificate
active
07052685
ABSTRACT:
A method and composition for treatment of advanced cutaneous T cell lymphoma is provided which involves administration of recombinant interleukin-12.
REFERENCES:
S. L. Lee et al. The regulation and biological activity of interleukin-12. May 1998. Leukemia and Lymphoma, 29(5-6): 427-38.
T. Osaki et al. IFN-gamma-inducing factor/IL-18 administation mediates IFN-gamma and IL-12-independent antitumor effects. Feb. 15, 1998, J. Immunol., 160:1742-1749.
Brunda, et al., “Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors”,J. Exp. Med.1993 178:869-879.
Diamandidou, E., et al., “Mycosis Fungoides and Sezary Syndrome”,Blood1996 88:2385-2409.
Haku, et al., “Interleukin-12-Mediated Killer Activity in Lung Cancer Patients”,Cytokine1997 9:846-852.
Hiramatsu, K., et al., “Generation of killer activity by interleukin-12 of mononuclear cells in malignant pleural effusions due to lung cancer”,Cancer Immunol. Immunother.1998 46:1-6.
Hsieh, C.S., et al., “Development of TH1 CD4+T Cells Through IL-12 Produced by Listeria-Induced Macrophages”,Science1993 260:547-549.
Nishimura, et al., “Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor”,Immunol. Lett.1995 48:149-152.
Rook, et al., “Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses”,Blood1999 94:902-908.
Rook, et al., “The Immunopathogenesis of Cutaneous T-Cell Lymphoma”,Arch. Dermatol.1993 129:486.
Rook, et al., “IL-12 Reverses Cytokine and Immune Abnormalities in Sezary Syndrome1”,J. Immunol.1995 154:1491-1498.
Rook, et al., “The Potential Therapeutic Role of Interleukin-12 in Cutaneous T-Cell Lymphomaα”,Ann. NY Acad. Sci.1996 795:310-318.
Rook, et al., “Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis”,Clin. Ex. Immunol.1997 107:16-20.
Sahin, et al., “Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors”,Cancer Immunol. Immunother.1996 42:9-14.
Seo N., et al., “Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-gamma (IFN-γ) and IL-12 and fluctuations in association with disease activity”,Clin. Exp. Immunol.1998 112:403-409.
Verbik, et al., “In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma”,Clin. Exp. Metastasis1996 42:219-229.
Vowels, et al., “Aberrant Cytokine Production by Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells”,J. Invest. Dermatol.1992 99:90-94.
Vowels, et al., “Th2 cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma”,J. Invest. Dermatol.1994 103:669-673.
Vowels, et al., “Normalization of Cytokine Secretion Patterns and Immune Function Following Disappearance of Malignant Clone from the Peripheral Blood of a Sezary Syndrome (SzS) Patient”,J. Invest. Dermatol.1993 100:556.
Brumback Brenda
Jiang Dong
Licata & Tyrrell P.C.
Trustees of the University of Pennsylvania
LandOfFree
Methods for treatment of cutaneous T-cell lymphoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of cutaneous T-cell lymphoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of cutaneous T-cell lymphoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3592537